ArticleFrontiers in oncology2026
The unusual first sign of presentation of hepatocellular carcinoma: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, characterized by aggressive biological behavior and a high propensity for extrahepatic spread. The most common sites of metastasis are the lungs, regional lymph nodes, bones, adrenal glands, and peritoneum. In contrast, the paranasal sinuses are an unusual site for metastatic HCC, and involvement of the sphenoid sinus represents an even rarer event. Case description: We report the case of a 67-year-old male patient who presented with transient diplopia, left eyelid ptosis, and refractory epistaxis as the initial clinical manifestations of a previously undetected HCC. Histopathological evaluation of the sinus mass and subsequent imaging confirmed a metastatic lesion from a silent primary liver tumor. The patient was managed using a multidisciplinary approach, undergoing radiation therapy to the sphenoid sinus for pain control and endovascular embolization of the sphenopalatine arteries for refractory epistaxis. In March 2026, a contrast-enhanced computed tomography (CT) scan revealed new osteolytic lesions, consistent with bone metastases, involving the proximal third of the left clavicle and the T9 vertebral body. The patient subsequently received further palliative radiotherapy to the left clavicle and T7-T9, and initiated first-line systemic therapy with atezolizumab plus bevacizumab, completing four cycles. Due to disease progression at multiple skeletal sites and in the sphenoid region, as revealed by a CT scan in June 2026, second-line treatment with lenvatinib was initiated and is ongoing at the latest follow-up. Conclusions: Despite its rarity, the differential diagnosis of a paranasal sinus lesion should include the possibility of metastasis from HCC, particularly in patients with underlying chronic liver disease. Histopathological confirmation and a multidisciplinary approach are critical for optimizing therapeutic planning in this challenging clinical scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.